HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial.

AbstractBACKGROUND:
Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering from dyskinesias.
METHODS:
In this multi-center, double-blind, randomized, placebo-controlled, cross-over trial, 36 patients with Parkinson's disease and dyskinesias were randomized, and 62 interventions, which included amantadine (300 mg/day) or placebo treatment for 27 days, were analyzed. At 15 days after washout, the treatments were crossed over. The primary outcome measure was the changes in the Rush Dyskinesia Rating Scale (RDRS) during each treatment period. The secondary outcome measures were changes in the Unified Parkinson's Disease Rating Scale part IVa (UPDRS-IVa, dyskinesias), part IVb (motor fluctuations), and part III (motor function).
RESULTS:
RDRS improved in 64% and 16% of patients treated with amantadine or placebo, respectively, with significant differences between treatments. The adjusted odds-ratio for improvement by amantadine was 6.7 (95% confidence interval, 1.4 to 31.5). UPDRS-IVa was improved to a significantly greater degree in amantadine-treated patients [mean (SD) of 1.83 (1.56)] compared with placebo-treated patients [0.03 (1.51)]. However, there were no significant effects on UPDRS-IVb or III scores.
CONCLUSIONS:
Results from the present study demonstrated that amantadine exhibited efficacious effects against dyskinesias in 60-70% of patients.
TRIAL REGISTRATION:
UMIN Clinical Trial Registry UMIN000000780.
AuthorsHideyuki Sawada, Tomoko Oeda, Sadako Kuno, Masahiro Nomoto, Kenji Yamamoto, Mitsutoshi Yamamoto, Kinya Hisanaga, Takashi Kawamura,
JournalPloS one (PLoS One) Vol. 5 Issue 12 Pg. e15298 ( 2010) ISSN: 1932-6203 [Electronic] United States
PMID21217832 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antiparkinson Agents
  • Placebos
  • Amantadine
Topics
  • Adult
  • Aged
  • Amantadine (pharmacology)
  • Antiparkinson Agents (pharmacology)
  • Cross-Over Studies
  • Double-Blind Method
  • Dyskinesias (drug therapy)
  • Female
  • Humans
  • Intervention Studies
  • Male
  • Middle Aged
  • Parkinson Disease (drug therapy)
  • Placebos
  • Quality of Life

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Research Interface PRO additionally includes drill-down to evidence, articles by author, export to Excel, FDA Link and mobile subscription:
1 year subscription, $490.00 USD